Genetic Counseling & Ethics in Neurogenetics
5 sections · 20 min
The Genetic Counseling Process
Genetic counseling helps individuals and families understand and adapt to the implications of genetic contributions to disease. The guiding principle is non-directiveness — balanced information, autonomous decision-making.
Pre-test counseling
- Three-generation pedigree: inheritance patterns, affected relatives, consanguinity, ethnicity
- Risk assessment integrating pedigree + clinical presentation
- Test selection: gene panel vs. exome vs. genome vs. repeat expansion testing
- Discuss the full range of possible outcomes: definitive diagnosis, VUS, secondary/incidental findings (ACMG v3.2 actionable genes), and unexpected findings (non-paternity, consanguinity)
Informed consent must cover: purpose, result types, test limitations, family implications, insurance considerations, and the right to decline.
Post-test counseling: result disclosure in a supportive setting, phenotype correlation, psychosocial support, specialist referral, and — for uninformative results — discussion of residual risk and future re-analysis.
Key Points
- Pre-test: pedigree, risk assessment, test selection, and discussion of all possible outcome types (diagnostic, VUS, incidental, non-paternity)
- Informed consent: purpose, result types, limitations, family implications, insurance, right to decline
- Non-directiveness: balanced information, autonomous decision-making — the counselor does not steer choices
- Post-test: result disclosure, psychosocial support, specialist coordination, and re-analysis planning for uninformative results
✦ Check Your Understanding
A clinical exome sequencing report identifies a variant of uncertain significance (VUS) in KCNQ2 in a 3-month-old infant with neonatal-onset epilepsy. The infant's seizures are well controlled on carbamazepine. During counseling, the parents ask whether this VUS confirms their child's diagnosis. What is the most appropriate counseling approach?
Select an answer to reveal the explanation
Predictive and Presymptomatic Testing
Predictive testing determines whether a healthy at-risk individual carries a variant that will or may cause future disease. It carries profound psychological, social, and legal implications.
Huntington disease (HD) — the paradigm
- AD, near-complete penetrance (CAG ≥40), no disease-modifying treatment
- International protocol requires: ≥2 pre-test counseling sessions with cooling-off period, psychological assessment (depression/suicidality screen), identified support person, no testing of minors without childhood intervention
- Results never disclosed by phone or to third parties without consent
The right not to know: at-risk individuals are never obligated to test. Testing a grandchild can inadvertently reveal an intervening parent's status — exclusion testing (linkage-based) may preserve the parent's right not to know.
Insurance (US): GINA (2008) protects against genetic discrimination by health insurers and employers but does NOT cover life, disability, or long-term care insurance. A positive HD result can legally be used to deny life insurance. Counsel patients about this gap before testing.
Psychological impact: ~10% of HD predictive testing recipients experience clinically significant adverse reactions (depression, anxiety, relationship disruption). Both positive and negative results can cause distress (survivor guilt, identity disruption).
Key Points
- HD predictive testing: ≥2 counseling sessions, psychological assessment, support person, no testing of minors without childhood intervention
- Right not to know: testing one family member can inadvertently reveal another's status; exclusion testing may preserve this right
- GINA protects health insurance/employment but NOT life, disability, or long-term care insurance — critical gap to discuss before testing
- ~10% experience clinically significant adverse psychological reactions; both positive and negative results can cause distress
✦ Check Your Understanding
A 28-year-old individual whose parent died of Huntington disease requests predictive testing. They have no neurological symptoms. According to the international HD predictive testing protocol, which of the following is required before testing can proceed?
Select an answer to reveal the explanation
Pediatric Genetic Testing Considerations
Testing children balances medical benefit of early diagnosis against the child's future autonomy.
Test when results are medically actionable in childhood
- TSC: genetic confirmation triggers surveillance (brain MRI, renal ultrasound, echo, ophthalmology) enabling early detection of SEGAs, AMLs, and cardiac complications
- SMA: disease-modifying therapies (nusinersen, Zolgensma, risdiplam) are dramatically more effective presymptomatically — making identification time-sensitive; see the Genetic Neuromuscular Disorders module
Defer testing for adult-onset conditions without childhood actionability (e.g., HD): ACMG/AAP recommend waiting until the individual can provide autonomous consent (typically age 18). Testing a child for HD removes their future right to choose.
Newborn screening (NBS): SMA added to US RUSP in 2018; all 50 states now screen. The expanding panel raises questions about inclusion thresholds for conditions with variable expressivity or uncertain treatment efficacy.
Genome-wide NBS (BabySeq, Guardian, UK Newborn Genomes Programme): potential to detect hundreds of treatable conditions, but concerns include VUS generation, adult-onset condition identification, parental anxiety, and the 'patient-in-waiting' phenomenon.
Key Points
- Test children when results are medically actionable (TSC surveillance, presymptomatic SMA treatment)
- Defer testing for adult-onset conditions without childhood intervention (e.g., HD) per ACMG/AAP — preserve future autonomy
- SMA added to US RUSP 2018; all 50 states screen; presymptomatic treatment dramatically improves outcomes
- Genome-wide NBS pilots raise concerns: VUS, future autonomy violations, parental anxiety, 'patient-in-waiting' phenomenon
✦ Check Your Understanding
The parents of a healthy 5-year-old boy with a family history of Huntington disease (affected grandfather) request predictive HD testing for their son. What is the most appropriate response?
Select an answer to reveal the explanation
Reproductive Options and Family Planning
Families with heritable neurogenetic conditions have multiple reproductive options. Counseling before conception enables informed, values-aligned decisions.
Carrier screening: ACOG recommends pan-ethnic expanded panels (100–400+ genes) for all individuals who are pregnant or considering pregnancy. Includes SMA, Tay-Sachs, Canavan, Fragile X premutation, and others.
Prenatal diagnosis (when both partners carry risk):
- CVS (10–13 weeks) or amniocentesis (15–20 weeks) — definitive fetal diagnosis; ~0.1–0.3% procedure-related miscarriage risk
PGT-M (preimplantation genetic testing for monogenic disorders): IVF with blastocyst biopsy → only unaffected embryos transferred. Available for virtually any monogenic condition with a known variant (HD, SMA, TSC, SCN1A). Requires custom probe development (~4–6 weeks).
NIPS (cell-free DNA): highly accurate for common aneuploidies (trisomy 21/18/13) but has a high false positive rate for rare microdeletions (e.g., 22q11.2) due to low positive predictive value. A positive NIPS for a rare condition always requires confirmatory CVS/amniocentesis.
Reproductive autonomy is a cornerstone principle. Disability rights perspectives challenge assumptions about preventing genetic conditions. Counselors present balanced, non-directive information. Additional options include donor gametes, embryo donation, and adoption.
Key Points
- ACOG recommends pan-ethnic expanded carrier screening (100–400+ genes) for all individuals pregnant or considering pregnancy
- CVS (10–13 wk) or amniocentesis (15–20 wk) for definitive prenatal diagnosis; PGT-M with IVF for pre-pregnancy embryo selection
- NIPS is accurate for common aneuploidies but has high false positive rate for rare microdeletions — always confirm with diagnostic testing
- Reproductive autonomy and disability rights perspectives must be respected; non-directive counseling is essential
✦ Check Your Understanding
A couple in which the mother is a carrier of an SMN1 deletion (SMA carrier) and the father is also confirmed as a carrier seeks counseling about reproductive options. They wish to avoid prenatal diagnosis with possible termination. Which option best addresses their preference?
Select an answer to reveal the explanation
Ethical Frameworks and Emerging Challenges
Genomic medicine raises ethical questions that outpace existing guidelines.
Duty to recontact: when VUS are reclassified (to P/LP or B/LB), should labs recontact patients? Ethically supported but not universally mandated. Best practice: systematic re-analysis workflows and upfront communication that reclassification may occur.
Data sharing: ClinVar and DECIPHER improve variant classification through aggregated data. Contributing de-identified data is ethically supported (beneficence); consent should address this.
Direct-to-consumer (DTC) testing: 23andMe reports APOE ε4 and select BRCA founder mutations, but screens only limited variants — a negative DTC BRCA result does NOT exclude pathogenic variants. DTC results must be confirmed by clinical-grade testing before medical decisions.
Equity and access: ~6,000 certified genetic counselors in the US (far below need). Underrepresented populations in gnomAD/ClinVar receive higher VUS rates → diagnostic inequity. Telegenetics has expanded access but disparities persist.
Emerging frontiers
- Polygenic risk scores for neuropsychiatric conditions: limited utility, poor cross-ancestry performance, risk of genetic determinism
- Somatic gene editing (CRISPR for sickle cell) is now clinically approved; germline editing remains prohibited in most jurisdictions
Key Points
- Duty to recontact on reclassification: ethically supported but not mandated; establish re-analysis workflows upfront
- DTC testing screens only select variants — negative results do NOT exclude pathogenic variants; require clinical-grade confirmation
- Database underrepresentation of minority populations → higher VUS rates → diagnostic inequity; telegenetics is a partial solution
- Polygenic risk scores have limited clinical utility and poor cross-ancestry performance; somatic gene editing is approved but germline editing is prohibited
✦ Check Your Understanding
A clinical genetics laboratory reclassifies a previously reported VUS in TSC2 to likely pathogenic based on new functional data and additional affected individuals in ClinVar. The patient was tested 3 years ago. What is the current best practice regarding recontacting the patient?
Select an answer to reveal the explanation
0 of 5 sections read
Scroll through all sections to track your progress.